Translation of "Screened patients" in German

Patients screened had type 2 diabetes were treated with basal insulin for at least 6 months, receiving a stable daily dose of between 15 and 40 U alone or combined with 1 or 2 OADs (metformin or a sulfonylurea or a glinide or a SGLT-2 inhibitor or a DPP-4 inhibitor), had an HbA1c between 7.5% and 10% (mean HbA1c of 8.5% at screening) and a FPG less than or equal to 10.0 mmol/L or 11.1 mmol/L depending on their previous anti-diabetic treatment.

Patients screened positive for hepatitis B or C were excluded from clinical trials.

In clinical trials, tofacitinib was not evaluated in subjects with severe (Child Pugh C) hepatic impairment (see sections 4.2 and 4.4), or in patients screened positive for hepatitis B or C.

All patients should be screened, in particular patients over the age of 65, for renal dysfunction by obtaining a history and/ or laboratory tests.

Of the 300 patients screened, only 25 had either a history or skin prick tests or RAST responses suggestive of food allergy.

"Healthy Heart For All" program by the numbers: 120 facilities, 22 cities, 1,200 physicians, 147,000 patients screened, 14,000 patients treated.

For patients, screening and diagnosis can make the difference between life and death.

It is necessary for "screening out" patients with obesity.

Balanced and evidence-based patient information on cancer screening can protect patients from inadequate medical advice.

For these reasons, CHMP could not identify cancer screening methods that patients would benefit from.

Genetic screening of human patients established mutations in both genes as causal for human disease.

At screening, patients were required to have had at least one exacerbation in the previous year and on standard of care COPD maintenance treatment for at least 12 weeks.

At screening 64.4% of patients were receiving insulin glargine as basal insulin and 95.0% received at least 1 concomitant OAD.

Randomised patients could have been pre-treated with UFH during the screening phase but patients treated for more than 24 hours with therapeutic dose of anticoagulant or with uncontrolled hypertension were excluded.

EGFR mutation status was determined for each patient prior to patient screening and 154 patients were randomised to receive either erlotinib + Avastin (erlotinib 150 mg oral daily + Avastin [15 mg/kg IV every 3 weeks]) or erlotinib monotherapy (150 mg oral daily) until disease progression (PD) or unacceptable toxicity.

The study will also provide data on pregnancies in women taking the medicine, and on healthcare professionals' compliance with the recommendations to screen and monitor patients before and during treatment.

After optimizing the OCS dose during the screening period, patients received 300 mg dupilumab (n=103) or placebo (n=107) once every other week for 24 weeks following an initial dose of 600 mg or placebo.